Advertisement

Journal of Cancer Survivorship

, Volume 12, Issue 6, pp 794–802 | Cite as

Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer

  • Matthew P. Banegas
  • Marc A. Emerson
  • Alyce S. Adams
  • Ninah S. Achacoso
  • Neetu Chawla
  • Stacey Alexeeff
  • Laurel A. Habel
Article

Abstract

Purpose

To investigate the implications of a cancer diagnosis on medication adherence for pre-existing comorbid conditions, we explored statin adherence patterns prior to and following a new diagnosis of breast, colorectal, or prostate cancer among a multi-ethnic cohort.

Methods

We identified adults enrolled at Kaiser Permanente Northern California who were prevalent statin medication users, newly diagnosed with breast, colorectal, or prostate cancer between 2000 and 2012. Statin adherence was measured using the proportion of days covered (PDC) during the 2-year pre-cancer diagnosis and the 2-year post-cancer diagnosis. Adherence patterns were assessed using generalized estimating equations, for all cancers combined and stratified by cancer type and race/ethnicity, adjusted for demographic, clinical, and tumor characteristics.

Results

Among 10,177 cancer patients, statin adherence decreased from pre- to post-cancer diagnosis (adjusted odds ratio (ORadj):0.91, 95% confidence interval (95% CI):0.88–0.94). Statin adherence decreased from pre- to post-cancer diagnosis among breast (ORadj:0.94, 95% CI:0.90–0.99) and colorectal (ORadj:0.79, 95% CI:0.74–0.85) cancer patients. No difference in adherence was observed among prostate cancer patients (ORadj:1.01, 95% CI:0.97–1.05). Prior to cancer diagnosis, adherence to statins was generally higher among non-Hispanic whites and multi-race patients than other groups. However, statin adherence after diagnosis decreased only among these two populations (ORadj:0.85, 95% CI:0.85–0.92 and ORadj:0.86, 95% CI:0.76–0.97), respectively.

Conclusions

We found substantial variation in statin medication adherence following diagnosis by cancer type and race/ethnicity among a large cohort of prevalent statin users in an integrated health care setting.

Implications for Cancer Survivors

Improving our understanding of comorbidity management and polypharmacy across diverse cancer patient populations is warranted to develop tailored interventions that improve medication adherence and reduce disparities in health outcomes.

Keywords

Adherence Race/ethnicity Breast cancer Colorectal cancer Prostate cancer Comorbidities 

Notes

Acknowledgements

Parts of this study were presented at the 8th American Association for Cancer Research Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. The study sponsor had no role in study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the report.

Funding

This work was supported by PHS grant from the National Cancer Institute (R01 CA098838, Habel, PI; R01AG032249, Adams, PI; Cancer Research Network: U24 CA17152, Kushi, PI).

Compliance with ethical standards

Conflict of interest

MPB has received research grants from AstraZeneca, and LAH has received research grants from Genentech, for projects outside of this work.

Ethical approval

This study was a secondary analysis of existing dataset with no PHI and, therefore, did not meet the definition of human subject research. For this type of study, formal consent is not required.

Supplementary material

11764_2018_716_MOESM1_ESM.docx (23 kb)
Supplemental Table 1 (DOCX 22 kb)
11764_2018_716_MOESM2_ESM.docx (35 kb)
Supplemental Table 2 (DOCX 34 kb)
11764_2018_716_MOESM3_ESM.docx (51 kb)
Supplemental Figure 1 (DOCX 51 kb)

References

  1. 1.
    American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018.Google Scholar
  2. 2.
    Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.CrossRefGoogle Scholar
  3. 3.
    Smith AW, Reeve BB, Bellizzi KM, Harlan LC, Klabunde CN, Amsellem M, et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev. 2008;29(4):41–56.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Deckx L, et al. Chronic diseases among older cancer survivors. J Cancer Epidemiol. 2012;2012:206414.CrossRefGoogle Scholar
  5. 5.
    Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.CrossRefGoogle Scholar
  6. 6.
    Cashman J, Wright J, Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18(5):651–5.CrossRefGoogle Scholar
  7. 7.
    Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7(6):371–4.CrossRefGoogle Scholar
  8. 8.
    Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a diagnosis of cancer among Medicare beneficiaries with diabetes. J Oncol Pract. 2015;11(6):429–34.CrossRefGoogle Scholar
  9. 9.
    Calip GS, Boudreau DM, Loggers ET. Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat. 2013;138(1):225–33.CrossRefGoogle Scholar
  10. 10.
    Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf. 2014;24(1):75–85.CrossRefGoogle Scholar
  11. 11.
    Yang J, Neugut AI, Wright JD, Accordino M, Hershman DL. Nonadherence to oral medications for chronic conditions in breast cancer survivors. J Oncol Pract. 2016;12(8):e800–9.CrossRefGoogle Scholar
  12. 12.
    Chou YT, Winn AN, Rosenstein DL, Dusetzina SB. Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiol Drug Saf. 2017;26(6):676–84.CrossRefGoogle Scholar
  13. 13.
    Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22(11):1572–8.CrossRefGoogle Scholar
  14. 14.
    Poon I, Lal LS, Ford ME, Braun UK. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother. 2009;43(2):185–93.CrossRefGoogle Scholar
  15. 15.
    Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, et al. Medication adherence and racial differences in A1C control. Diabetes Care. 2008;31(5):916–21.CrossRefGoogle Scholar
  16. 16.
    Zhang Y, Baik SH. Race/ethnicity, disability, and medication adherence among Medicare beneficiaries with heart failure. J Gen Intern Med. 2014;29(4):602–7.CrossRefGoogle Scholar
  17. 17.
    Adams AS, Uratsu C, Dyer W, Magid D, O’Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173(1):54–61.CrossRefGoogle Scholar
  18. 18.
    Heart Protection Study Collaborative, G. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRefGoogle Scholar
  19. 19.
    Taylor F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816.Google Scholar
  20. 20.
    Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–24.CrossRefGoogle Scholar
  21. 21.
    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–45.CrossRefGoogle Scholar
  22. 22.
    Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRefGoogle Scholar
  23. 23.
    Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–85.CrossRefGoogle Scholar
  24. 24.
    Turin A, Pandit J, Stone NJ. Statins and nonadherence: should we RELATE better? J Cardiovasc Pharmacol Ther. 2015;20(5):447–56.CrossRefGoogle Scholar
  25. 25.
    Lemstra M, Blackburn D. Nonadherence to statin therapy: discontinuation after a single fill. Can J Cardiol. 2012;28(5):567–73.CrossRefGoogle Scholar
  26. 26.
    Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574–80.CrossRefGoogle Scholar
  27. 27.
    Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.CrossRefGoogle Scholar
  28. 28.
    Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388–92.PubMedGoogle Scholar
  29. 29.
    Oehrli MD, Quesenberry CP. Northern California cancer registry: 2015 annual report on trends, incidence, and outcomes. Oakland, CA: Kaiser Permanente; 2015.Google Scholar
  30. 30.
    Nau DP. Proportion of days covered (PDC) as the preferred method of measuring medication adherence. 02/01/2016]; Available from: www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf.
  31. 31.
    Nichol MB, Knight TK, Wu J, Tang SSK, Cherry SB, Benner JS, et al. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health. 2009;12(4):544–50.CrossRefGoogle Scholar
  32. 32.
    Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51–7.PubMedGoogle Scholar
  33. 33.
    Fitzmaurice GM, Laird NM, Ware JH, editors. Applied longitudinal analysis. Second ed. New York, New York: John Wiley and Sons; 2011.Google Scholar
  34. 34.
    Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–50.CrossRefGoogle Scholar
  35. 35.
    Shin DW, Park JH, Park JH, Park EC, Kim SY, Kim SG, et al. Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Support Care Cancer. 2010;19(2):211–20.CrossRefGoogle Scholar
  36. 36.
    Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park). 2008;22(9):1052–5 discussion 1055, 1058, 1060.Google Scholar
  37. 37.
    daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386–96.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.CrossRefGoogle Scholar
  39. 39.
    Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35(5):535–43.CrossRefGoogle Scholar
  40. 40.
    Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907–12.CrossRefGoogle Scholar
  41. 41.
    Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489–96.CrossRefGoogle Scholar
  42. 42.
    Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55(2):117–42.CrossRefGoogle Scholar
  43. 43.
    LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16(7):e333–41.CrossRefGoogle Scholar
  44. 44.
    Gatwood J, Bailey JE. Improving medication adherence in hypercholesterolemia: challenges and solutions. Vasc Health Risk Manag. 2014;10:615–25.CrossRefGoogle Scholar
  45. 45.
    Jacobsen PB, DeRosa AP, Henderson TO, Mayer DK, Moskowitz CS, Paskett ED, et al. Systematic review of the impact of cancer survivorship care plans on health outcomes and health care delivery. J Clin Oncol. 2018;36(20):2088–100.CrossRefGoogle Scholar
  46. 46.
    Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer. 2017;123(8):1453–63.CrossRefGoogle Scholar
  47. 47.
    Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6):481–96.CrossRefGoogle Scholar
  48. 48.
    Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11.CrossRefGoogle Scholar
  49. 49.
    Kaul S, Avila JC, Mehta HB, Rodriguez AM, Kuo YF, Kirchhoff AC. Cost-related medication nonadherence among adolescent and young adult cancer survivors. Cancer. 2017;123(14):2726–34.CrossRefGoogle Scholar
  50. 50.
    Adams AS, Madden JM, Zhang F, Soumerai SB, Gilden D, Griggs J, et al. Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Med Care. 2014;52(8):695–703.CrossRefGoogle Scholar
  51. 51.
    Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.CrossRefGoogle Scholar
  52. 52.
    Yang Y, Thumula V, Pace PF, Banahan BF III, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178–88 discussion 2150-1.CrossRefGoogle Scholar
  53. 53.
    Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54–65.CrossRefGoogle Scholar
  54. 54.
    Ritchey M, Chang A, Powers C, Loustalot F, Schieb L, Ketcham M, et al. Vital signs: disparities in antihypertensive medication nonadherence among Medicare part D beneficiaries - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(36):967–76.CrossRefGoogle Scholar
  55. 55.
    Calip GS, Elmore JG, Boudreau DM. Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. Breast Cancer Res Treat. 2017;161(1):161–72.CrossRefGoogle Scholar
  56. 56.
    Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250–62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Health ResearchKaiser Permanente NorthwestPortlandUSA
  2. 2.Gillings School of Global Public HealthUniversity of North CarolinaChapel HillUSA
  3. 3.Division of ResearchKaiser PermanenteOaklandUSA

Personalised recommendations